The global menopause treatment market is expanding as the growing global population of menopausal women, increasing awareness of menopause-related health conditions, and rising demand for symptom management therapies support market expansion.

The market was valued at approximately USD 17.2 billion in 2024, about USD 18.08 billion in 2025, and is projected to reach roughly USD 29.79 billion by 2035, growing at a CAGR of approximately 5.12%. Growth is supported by aging population and demographic shifts, increasing awareness of menopause symptoms, advancements in treatment technologies, increased focus on women's health initiatives, and growing demand for natural and alternative therapies.marketresearchfuture

According to the World Health Organization (WHO), by 2030, approximately 1.2 billion women worldwide will be aged 50 years and older, significantly increasing the population seeking menopause management solutions and long-term women's healthcare services.

Hormone Replacement Therapy (HRT) emerged as the largest segment, commanding a substantial market share of 56.8%. HRT has traditionally been favored for its efficacy in alleviating menopausal symptoms, including vasomotor symptoms, sleep disturbances, and other menopause-related conditions.

Non-Hormonal Therapy is the fastest-growing area, appealing to women who prefer alternative options to HRT. This shift is fueled by increasing consumer awareness regarding the potential risks associated with HRT and a rising preference for natural treatment methods.

Key players include AbbVie, Bristol-Myers Squibb, Pfizer, Mylan, Amgen, Teva Pharmaceuticals, HRA Pharma, Bayer, and Novartis.

Read more: Menopause Treatment Market Size, Growth Statistics

People Also Ask

Q1. What is driving the menopause treatment market?
Aging population, increasing awareness of menopause symptoms, advancements in treatment technologies, women's health initiatives, and demand for natural therapies are major drivers.

Q2. Which treatment type leads the market?
Hormone Replacement Therapy (HRT) leads with 56.8% market share, while Non-Hormonal Therapy is the fastest-growing segment.

Tags: menopause treatment, hormone replacement therapy, non-hormonal therapy, women's health, aging population